Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	2.13T +36.6%
Revenue (ttm)	1.54T +8.8%
Net Income	93.19B -10.0%
EPS	8,098.18 -10.0%
Shares Out	11.51M
PE Ratio	22.86
Forward PE	13.35
Dividend	600.00 (0.31%)
Ex-Dividend Date	Dec 29, 2025

Volume	46,349
Average Volume	40,673
Open	193,600
Previous Close	194,000
Day's Range	185,000 - 193,600
52-Week Range	109,000 - 199,400
Beta	0.06
RSI	59.78
Earnings Date	Feb 9, 2026

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,644
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2024, Daewoong Pharmaceutical's revenue was 1.42 trillion, an increase of 3.44% compared to the previous year's 1.38 trillion. Earnings were 24.73 billion, a decrease of -79.68%.